Farmas USA

AGEN BCRX XOMA

AGEN, lástima que haya seguido el retroceso general de la última hora o media hora, porqué casi ha tocado los 3$....

BCRX, veremos si consigue mantener el verde o cierra en negativo...si antes de dar resultados de esos primeros 24 pacientes volviera a los 3$; igual me subo al carro de nuevo, a ver qué pasa..No entiendo mucho de AT, pero creo que esa vela de hoy es muy fea....martillo invertido, creo que se llama....

XOMA, bajando un 4,30% con una vela que tiene pinta de seguir bajando...esperando una buena corrección, lo más cercana posible a los 15/16 euros, por donde pasa la alcista desde 2017, para cargar y dejarlas en barbecho....

BCRX 
Shooting Star

 

  https://www.fiercebiotech.com/biotech/congressman-calls-sec-to-look-into-leaked-remdesivir-data-report?mkt_tok=eyJpIjoiTjJNM09UTXpOakUwWXpJdyIsInQiOiJDNklvQ2ljK0I2aEgwV3J3UVU1eTFxR3VQSmU0QWNzaTlKTlhzYzRjekY1Tk9WR3JCYndlT2RkRUs0aHNCTFU4UTJrQlJyRXZGS01iMXVsNG5aUDJtU2lGa1VjNWg5WEZzMGxYUkpiYnlUbkJuc1h2UDQya3Mza1NoTmtDXC9XNHhncFBWQTQ1QSs5WmNWNDhKUHdoWWdBPT0ifQ%3D%3D&mrkid=122817369 

BCRX

 "JMP Securities biotech analysts to hold an analyst/industry conference call 10:25 BCRX Biotech Analysts discuss Galidesivir, an antiviral therapy for COVID-19 in advanced development by Biocryst on an Analyst/Industry conference call to be held on Wednesday, April 22, 2020." 

¿Qué opinais de esto?  Parece demasiado evidente para ser bueno.... en stocktwits ya están pumpeando la noticia....

Esperar, ver y decidir....

Un saludo

  

https://seekingalpha.com/article/4338750

La mayor oportunidad de mercado de 2020: CORONAVIRUS.

https://pennystocks.com/penny-stock-sectors/biotech-stocks/2020/04/19/biggest-market-opportunity-in-2020-coronavirus-penny-stocks/?utm_source=DH_AGNPF&utm_medium=DH_AGNPF&utm_campaign=DH_AGNPF&utm_term=Finance.Yahoo.com_DH_AGNPF

CBIO

Datos de fase IIb positivos y sin anticuerpos neutralizantes.

The open-label Phase 2b study was designed to evaluate the ability of DalcA to maintain steady state protective FIX levels above 12% in six individuals with severe hemophilia B. Each subject received a single intravenous dose, followed by daily SQ doses of DalcA for 28 days. Data presented at the EAHAD Congress in February showed that daily SQ dosing of DalcA achieved effective prophylaxis with FIX activity levels ranging from 14-28% and zero bleeds. No neutralizing antibodies were detected and the treatment was well tolerated. The half-life of SQ DalcA ranged from 70-112 hours, suggesting the potential for lower or less frequent dosing.

http://ir.catalystbiosciences.com/news-releases/news-release-details/catalyst-biosciences-completes-phase-2b-trial-subcutaneous